Novi Francesca, Millan Mark J, Corsini Giovanni U, Maggio Roberto
Department of Neuroscience, University of Pisa, Pisa, Italy.
J Neurochem. 2007 Aug;102(4):1410-24. doi: 10.1111/j.1471-4159.2007.04660.x. Epub 2007 May 26.
Aripiprazole and the candidate antipsychotics, S33592, bifeprunox, N-desmethylclozapine (NDMC) and preclamol, are partial agonists at D(2) receptors. Herein, we examined their actions at D(2L) and D(3) receptors expressed separately or together in COS-7 cells. In D(2L) receptor-expressing cells co-transfected with (D(3) receptor-insensitive) chimeric adenylate cyclase-V/VI, drugs reduced forskolin-stimulated cAMP production by approximately 20% versus quinpirole (48%). Further, quinpirole-induced inhibition was blunted by aripiprazole and S33592, confirming partial agonist properties. In cells co-transfected with equal amounts of D(2L)and D(3) receptors (1 : 1), efficacies of aripiprazole and S33592 were attenuated. Further, in cells co-transfected with D(2L) and an excess of D(3) receptors (1 : 3), aripiprazole and S33592 were completely inactive, and they abolished the actions of quinpirole. Likewise, bifeprunox, NDMC and preclamol lost agonist properties in cells co-transfected with D(2L)and D(3) receptors. Accordingly, at split D(2trunk)/D(3tail) and D(3trunk)/D(2tail) chimeras, agonist actions of quinpirole were blocked by aripiprazole and S33592 that, like bifeprunox, NDMC and preclamol, were inactive alone. Conversely, when a 12 amino acid sequence in the third intracellular loop of D(3) receptors was replaced by the homologous sequence of D(2L) receptors, aripiprazole, S33592, bifeprunox, NDMC and preclamol inhibited cAMP formation by approximately 20% versus quinpirole (42%). Moreover, at D(2L) receptor-expressing cells co-transfected with modified D(3i3(D2)) receptors, drugs behaved as partial agonists. To summarize, low efficacy agonist actions of aripiprazole, S33592, bifeprunox, NDMC and preclamol at D(2L) receptors are abrogated upon co-expression of D(3) receptors, probably due to physical association and weakened coupling efficacy. These findings have implications for the functional profiles of antipsychotics.
阿立哌唑以及候选抗精神病药物S33592、双苯氟嗪、N - 去甲基氯氮平(NDMC)和普瑞氯莫,都是D(2)受体的部分激动剂。在此,我们研究了它们在单独表达或共同表达于COS - 7细胞中的D(2L)和D(3)受体上的作用。在与(对D(3)受体不敏感的)嵌合腺苷酸环化酶 - V/VI共转染的表达D(2L)受体的细胞中,与喹吡罗(48%)相比,这些药物使福司可林刺激的cAMP产生减少了约20%。此外,阿立哌唑和S33592减弱了喹吡罗诱导的抑制作用,证实了它们的部分激动剂特性。在等量共转染D(2L)和D(3)受体(1:1)的细胞中,阿立哌唑和S33592的效力减弱。此外,在共转染D(2L)和过量D(3)受体(1:3)的细胞中,阿立哌唑和S33592完全无活性,并且它们消除了喹吡罗的作用。同样,双苯氟嗪、NDMC和普瑞氯莫在共转染D(2L)和D(3)受体的细胞中失去了激动剂特性。因此,在分裂的D(2trunk)/D(3tail)和D(3trunk)/D(2tail)嵌合体上,喹吡罗的激动剂作用被阿立哌唑和S33592阻断,而阿立哌唑和S33592与双苯氟嗪、NDMC和普瑞氯莫一样,单独无活性。相反,当D(3)受体第三细胞内环中的12个氨基酸序列被D(2L)受体的同源序列取代时,与喹吡罗(42%)相比,阿立哌唑、S33592、双苯氟嗪、NDMC和普瑞氯莫抑制cAMP形成约20%。此外,在与修饰的D(3i3(D2))受体共转染的表达D(2L)受体细胞中,这些药物表现为部分激动剂。总之,阿立哌唑、S33592、双苯氟嗪、NDMC和普瑞氯莫在D(2L)受体上的低效激动剂作用在共表达D(3)受体时被消除,这可能是由于物理缔合和偶联效力减弱所致。这些发现对抗精神病药物的功能特征具有启示意义。